Skip to content
ASCO 2014 logo

ASCO 2014

7 interviews

American Society of Clinical Oncology Annual Meeting

Interviews and expert commentary from ASCO 2014 — study authors and key opinion leaders discuss the findings and their clinical implications.

Official website ↗
Enzalutamide improves overall and progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer

Enzalutamide improves overall and progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer

SAN FRANCISCO— The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically determined progression-free survival in men whose metast

6 March 2014
Clear-cell renal cell cancer: first molecular prognostic marker also brings scope for drug targeting

Clear-cell renal cell cancer: first molecular prognostic marker also brings scope for drug targeting

SAN FRANCISCO— A recently discovered molecular prognostic biomarker for clear-cell renal cell cancer has been validated and shown to indicate a four-fold increase in risk of adverse cancer-specific su

27 February 2014
Metastatic renal cell carcinoma: biomarkers to guide future therapy

Metastatic renal cell carcinoma: biomarkers to guide future therapy

SAN FRANCISCO— Plasma and tumor biomarkers including FGF, C-KIT and VEG-F were found to yield prognostic information which could help guide therapies, according to research findings presented at the 2

25 February 2014
Initial Gleason score does not predict abiraterone response in patients with metastatic castration-resistant prostate cancer

Initial Gleason score does not predict abiraterone response in patients with metastatic castration-resistant prostate cancer

SAN FRANCISCO— Gleason score at initial diagnosis was not predictive of response to abiraterone in patients with metastatic castration-resistant prostate cancer in a pooled analysis of three trials of

12 February 2014
Responses to enzalutamide after prior abiraterone therapy in men with castration-resistant metastatic prostate cancer

Responses to enzalutamide after prior abiraterone therapy in men with castration-resistant metastatic prostate cancer

SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen depri

11 February 2014
PSA-membrane antibody conjugate shows promise for treating metastatic castration-resistant, taxane-refractory prostate cancer

PSA-membrane antibody conjugate shows promise for treating metastatic castration-resistant, taxane-refractory prostate cancer

SAN FRANCISCO—A “guided missile” approach to treating metastatic, castration-resistant, taxane-refractory prostate cancer demonstrated success at the 2014 ASCO Genitourinary Cancers Sympos

6 February 2014
Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds

Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds

SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “a

6 February 2014